Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 182

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline

Open access
Ryan, Joanne, Storey, Elsdon, Murray, Anne M., Woods, Robyn L., Wolfe, Rory, Reid, Christopher M., Nelson, Mark R., Chong, Trevor T.J., Williamson, Jeff D., Ward, Stephanie A., Lockery, Jessica E., Orchard, Suzanne G., Trevaks, Ruth, Kirpach, Brenda, Newman, Anne B., Ernst, Michael E., McNeil, John J., Shah, Raj C., on behalf of the ASPREE Investigator Group · 2020 · Neurology

Abstract

OBJECTIVE: To determine the effect of low-dose aspirin vs placebo on incident all-cause dementia, incident Alzheimer disease (AD), mild cognitive impairment (MCI), and cognitive decline in older individuals. METHODS: Aspirin in Reducing Events in the Elderly (ASPREE) was a double-blind, placebo-controlled trial of low-dose aspirin. In the United States and Australia, community-dwelling individuals aged ≥70 years (US minorities ≥65 years) and free of cardiovascular disease, physical disability, and diagnosed dementia were enrolled. Participants were randomized 1:1-100 mg daily aspirin or placebo. The Modified Mini-Mental State Examination, Hopkins Verbal Learning Test-Revised, Symbol Digit Modalities Test, and Controlled Oral Word Association Test assessed cognition at baseline and over follow-up. Additional cognitive testing was performed in participants with suspected dementia ("trigger") based on within-study assessments or clinical history. Dementia was adjudicated according to DSM-IV criteria. National Institute on Aging-Alzheimer's Association criteria were used for AD and MCI subclassification. RESULTS: A total of 19,114 participants were followed over a median 4.7 years and 964 triggered further dementia assessments. There were 575 adjudicated dementia cases, and 41% were classified as clinically probable AD. There was no substantial difference in the risk of all dementia triggers (hazard ratio [HR], 1.03; 95% confidence interval [CI], 0.91-1.17), probable AD (HR, 0.96; 95% CI, 0.74-1.24), or MCI (HR, 1.12; 95% CI, 0.92-1.37) between aspirin and placebo. Cognitive change over time was similar in the aspirin and placebo groups. CONCLUSIONS: There was no evidence that aspirin was effective in reducing risk of dementia, MCI, or cognitive decline. Follow-up of these outcomes after initial exposure is ongoing. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for healthy older individuals, low-dose aspirin does not significantly reduce the incidence of dementia, probable AD, MCI, or cognitive decline. CLINICALTRIALSGOV IDENTIFIER: NCT01038583.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000009277

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 182

Metadata

Authors
Ryan, J., Storey, E., Murray, A. M., Woods, R. L., Wolfe, R., Reid, C. M., Nelson, M. R., Chong, T. T. J., Williamson, J. D., Ward, S. A., Lockery, J. E., Orchard, S. G., Trevaks, R., Kirpach, B., Newman, A. B., Ernst, M. E., McNeil, J. J., Shah, R. C., & on behalf of the ASPREE Investigator Group
Venue
Neurology
Published
2020-07-21
Volume
95
Issue
3
Pages
e320-e331
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W3013555770
Cited by
182
References
12
FWCI
17.23
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline. https://app.cochat.ai/papers/10.1212/wnl.0000000000009277
The paper
Ryan, J., Storey, E., Murray, A. M., Woods, R. L., Wolfe, R., Reid, C. M., Nelson, M. R., Chong, T. T. J., Williamson, J. D., Ward, S. A., Lockery, J. E., Orchard, S. G., Trevaks, R., Kirpach, B., Newman, A. B., Ernst, M. E., McNeil, J. J., Shah, R. C., & on behalf of the ASPREE Investigator Group. (2020). Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline. Neurology. https://doi.org/10.1212/wnl.0000000000009277

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.